Common mucosal system and immunity
Professor Robert Clancy announces some of his new research findings. The microbiome and using bacteria based preparations to impressive theraputic effect, often without expensive drugs.
https://www.trialsitenews.com/a/a-common-mucosal-protection-system-inclusive-of-microbiomes-and-local-immunity-cognisance-through-covid-fe9bbf21
The Covid pandemic drew attention to the distinctive system of mucosal immunity and its limited interplay with systemic immunity with which we were more familiar. The pandemic coincided with a period of fifty years from the recognition of a communicating mucosal immune system. John Bienenstock called this “The Common Mucosal Immune System” (CMS). Lessons relevant to Covid on the relevance of mucosal immunity to both the pathogenesis of disease and vaccination strategies were slowly learnt. Early in the pandemic, protracted changes in the intestinal microbiota were noted that correlated with the progress and severity of infection, and later were linked to development of post-Covid syndrome. The purpose of this review is to pull together through the lens of Covid-19 how a viral infection of the respiratory mucosal space connects with systemic immunity on one hand, and mucosa-related microbiota on the other, within a single integrated mucosal system, to create a carpet of protection. Infection within this unified system can induce changes in balance between microbiota and the relevant local immune response at distant mucosal sites, which in turn, can impact the outcome of the inciting infection in either a deleterious or beneficial manner. Within the broader framework that includes systemic immunity, outcomes of both infection and vaccination, reflect a controlled balance determined by downregulation via suppressor T cells seeded from mucosal sites of infection. The integrity of this comprehensive system has been queried based on regional differences. Such a view fails to recognise mechanisms of critical outcomes of Covid and its management, and opportunities for innovative therapeutic intervention. Variations throughout the mucosal apparatus such as “offsite” generation of airway immunity in the gut and differences in microbial characteristics of microbiomes, reflect adaptation to local influences without compromising the essential qualities of a global mucosal protection system: communication, integration, and cooperation. A central unifying factor for a “Mucosal Immune Microbiome Protection System” or MIMPS, is the idea that a single set of gut-associated lymphoid tissues characterised by specialised M cells, samples appropriate microbiome to generate global mucosal immune defence.
New mRNA vaccine trials
Intradermal Mycobacterium vaccae and obuense (IMM-101)
Oral Non-typeable Haemophilus influenzae (NTHi)
UK could be first country to offer norovirus jab against ‘winter vomiting bug’
New vaccine could stop people developing the highly infectious illness after early trial results found it creates a ‘strong immune response’
https://www.telegraph.co.uk/news/2024/10/23/norovirus-vaccine-winter-vomiting-bug-moderna-wes-streeting/
mRNA
Systemic distribution inevitable
Antigenic dose produced varies
Longevity of mRNA?
Use of synthetic base
Contamination from manufacturing process
https://www.nihr.ac.uk/news/uks-first-norovirus-mrna-vaccine-trial-launched
First Phase 3 randomised clinical trial
Nova 301 trial, mRNA-1403
Trivalent, targeting three major strains of norovirus
mRNA norovirus vaccine, UK wide, 39 sites
Sponsored by Moderna,
Trial evaluates the efficacy and safety of mRNA-1403
Aims to recruit 2,500 participants, UK, late October to early 2025
Some mobile sites for community visits
25,000 globally
Half mRNA, half placebo
18 years + but 60 + wanted
Single dose vaccine at the first visit – a jab given in the upper arm.
The trial lasts up to 25 months.
At least six in-person visits to the clinical trial site,
and five phone calls with the trial team.
Part of a 10-year partnership between Moderna and the UK Health Security Agency (UKHSA) on behalf of UK Government
https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research
UK Vaccine Innovation Pathway (VIP) and the NIHR working together to accelerate vaccine trials in the UK.
https://bepartofresearch.nihr.ac.uk/?utm_source=nihr-website&utm_medium=referral&utm_campaign=bpor-nova
Dr Patrick Moore, Chief Investigator of the trial
The UK is really pleased to be able to play an important role in helping find an effective vaccine against this highly contagious disease.
NIHR Chief Executive Professor Lucy Chappell
Leveraging the UK’s expertise in vaccine development, the DHSC through the NIHR and Moderna are delivering this large-scale trial at pace,
so that people across the UK and the world can benefit sooner.
From the NIHR site
the Nova 301 trial serves as a model for future collaborations between the public and private sectors in advancing medical research.
Norovirus
https://www.cdc.gov/norovirus/data-research/index.html#:~:text=Economic%20impact,-Norovirus%20illness%20is&text=Every%20year%2C%20norovirus%20is%20estimated,healthcare%20costs%20and%20lost%20productivity.
https://emedicine.medscape.com/article/224225-overview
Worldwide, about 1 out of every 5 cases of acute gastroenteritis is caused by norovirus.
Gastroenteritis typically develops 12-48 hours after ingestion of contaminated food or water or after contact with an infected individual.
Symptoms typically last for 24-72 hours.
All ages
Nausea and vomiting
Watery diarrhea
Possible dehydration
Abdominal cramps
Headaches
Low-grade fever
Myalgias and malaise
Norovirus genus
More than 40 different strains
GII.4 Sydney
Transmission
Person to person, direct contact, exposure to aerosols, fecal–oral routes.
ID50 = 10 virions
Professor Angus Dalgleish, full interview
World class discussion for the serious viewer. Professor Dalgleish informs us about several important topics: Problems encountered on his tour of Australia. Lessons learned from his research into cancer vaccines. The potential for ivermectin aid in cancer treatment. Vitamin D is essential in cancer treatment. Obvious mistakes in production of Covid vaccines. Evidence from virology for a lab leak of the covid virus. The existence of a simple bacterial preparation to treat sever cancers and infections which has been refused regulator approval.
New Vitamin D paper
Vitamin D: A key player in COVID‐19 immunity and lessons from the pandemic to combat immune‐evasive variants
https://link.springer.com/article/10.1007/s10787-024-01578-w
As of July 2024
775,754,322 confirmed cases of COVID-19
13,578,710,228 vaccine doses had been administered
It is unclear why some patients develop severe symptoms while others do not,
literature suggests a role for vitamin D.
Vitamin D plays a crucial role in the infection or in ameliorating the severity of symptoms.
VDD is associated with increased hospitalization of severely ill patients and increased levels of COVID-19-caused mortality.
The mechanism of action of vitamin D and vitamin D deficiency (VDD) is well understood.
Vitamin D levels and genetic variations in the vitamin D receptor (VDR) gene significantly impact the severity and out- comes of COVID-19,
especially in the infections caused by Delta and Omicron variants.
Furthermore, VDD causes immune system dysregulation upon infection with SARS-CoV-2,
indicating that vitamin D sufficiency is crucial in fighting against COVID-19 infection.
Potential role as a prophylactic and treatment adjunct.
Immunomodulatory and anti-inflammatory effects of vitamin D
Ability to enhance the efficacy of new antiviral drugs
Large- scale randomized trials are required to reach a definitive conclusion.
Mechanisms of action
Macrophages activated to produce defensive proteins and stimulate naïve T cells
Activate T lymphocytes and mature B lymphocytes into plasma cells
Prevents inflammation, vasoconstriction, and fibrosis of the lungs.
Prevents excess release of cytokines from macrophages
Prevents excessive CRP production in the liver
Vit D can reduce viral replication
Vitamin D can protect against ARDS, the main death-causing complication of COVID-19
Seven out of nine studies reviewed by Yisak
https://pubmed.ncbi.nlm.nih.gov/33447107/
have indicated a crucial role in vitamin D status in COVID-19 infection, prognosis, and mortality.
Vitamin D dose
To decrease the risk of contracting a new infection,
people at high risk of COVID-19 to take 10,000 IU d−1 of vitamin D for a few weeks,
followed by 5000 IU d−1 to raise the concentrations of the active form of vitamin D.
Blood levels
Levels below 12 ng/mL indicate severe deficiency.
Levels between 12 and 20 ng/mL suggest deficiency
Treatment recommended for levels below 30 ng/mL
Optimal levels are 30–60 ng/mL,
Recommended prophylactic dose
0–1 years, 400 IU/day (10 mcg)
over 1 year, 600 IU (15 mcg)
over 8 years, half an adult dose
Adults, 800– 2000 IU of cholecalciferol
Routine toxicity monitoring is unnecessary for doses under 10,000 IU/day
Governmrnt prevents me getting vaccinated
Introduction to the lectures given in Australia with Professor Angus Dalgleish.
Cancers
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
Mechanisms of action
IVM induces different programmed cell death patterns in different tumor cells,
the main form of IVM induced programmed cell death is apoptosis.
Apoptosis
Programmed cell death
Autophagy
Lysosomal-dependent form of programmed cell death.
Pyroptosis
Inflammatory cell death induced by inflammasomes.
Kathleen T Ruddy, MD
https://twitter.com/bobanderson77/status/1797002359521866017/video/1
https://rumble.com/v4vk4pw-oncologist-kathleen-rudy-reveals-horse-dewormer-aka-ivermectin-cure-cancer.html
https://twitter.com/DocRuddy
https://rumble.com/v4vk4pw-oncologist-kathleen-rudy-reveals-horse-dewormer-aka-ivermectin-cure-cancer.html
Forms of cancer
Breast cancer
A malignant tumor produced by gene mutation in breast epithelial cells
Digestive system cancer
Gastric cancer is one of the most common malignant tumors worldwide.
Hepatocellular carcinoma is the fourth leading cause of cancer death worldwide.
Urinary system cancer
Renal cell carcinoma is a fatal malignant tumor of the urinary system derived from renal tubular epithelial cells.
Prostate cancer is a malignant tumor derived from prostate epithelial cells
Hematological cancer
Leukemia is a type of malignant clonal disease caused by abnormal hematopoietic stem cells
Reproductive system cancer
Cervical cancer is one of the most common gynecological malignancies
Ovarian cancer is a malignant cancer that lacks early clinical symptoms and has a poor therapeutic response.
Brain glioma
Glioma is the most common cerebral tumor
Glioblastoma, median survival time of 14-17 months
Respiratory system cancer
Nasopharyngeal carcinoma is a malignant tumor derived from epithelial cells of the nasopharyngeal mucosa.
Lung cancer has the highest morbidity and mortality among cancers
Melanoma
The most common malignant skin tumor with a high mortality rate.
Other papers
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205794/
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
https://pubmed.ncbi.nlm.nih.gov/32474842/
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
https://www.nature.com/articles/s41523-021-00229-5
Abstract 2320: Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
https://aacrjournals.org/cancerres/article/82/12_Supplement/2320/701043/Abstract-2320-Ivermectin-suppresses-pancreatic
Video reviews
https://www.youtube.com/watch?v=vCgNaOvICsk
https://www.youtube.com/@dr.kathleenruddy1734/videos
https://www.youtube.com/watch?v=m_78xfHRHUY
https://www.youtube.com/watch?v=jaY2BeNnfy8
DNA in RNA vaccines
Summary of my interview with analytical virologist Dr. David J. Speicher,
Substack: https://drdavidjspeicher.substack.com/
GiveSendGo: https://drdavidjspeicher.substack.com/p/launching-my-give-send-go-campaign
Kevin’s Substack: https://anandamide.substack.com/p/vaccine-targeted-qpcr-of-cancer-cell?utm_source=profile&utm_medium=reader2
Report from Canadian virologist, Dr. David Speicher
https://www.dropbox.com/scl/fi/sb20elb520v6a1saxg9lj/240909-D-Speicher-Report.pdf?rlkey=dutcvd85gh80ebfs2ucdmorba&e=3&st=0jpsw84f&dl=0
Maria Gutschi: https://mariagutschi.substack.com/
Proof, DNA contamination report
Summary of my interview with analytical virologist Dr. David J. Speicher,
Substack: https://drdavidjspeicher.substack.com/
GiveSendGo: https://drdavidjspeicher.substack.com/p/launching-my-give-send-go-campaign
Kevin’s Substack: https://anandamide.substack.com/p/vaccine-targeted-qpcr-of-cancer-cell?utm_source=profile&utm_medium=reader2
Report from Canadian virologist, Dr. David Speicher
https://www.dropbox.com/scl/fi/sb20elb520v6a1saxg9lj/240909-D-Speicher-Report.pdf?rlkey=dutcvd85gh80ebfs2ucdmorba&e=3&st=0jpsw84f&dl=0
Maria Gutschi: https://mariagutschi.substack.com/
I see my cardiologist
Link for the full film First do no Pharm, https://cerealkillers.gumroad.com/l/nopharmfilm/drjohn
This is film isn't just an exposé – it's a call to arms. It will provide you with the knowledge and tools to fight back against a system that values profits over patients. We'll show you how to navigate this treacherous landscape, how to protect yourself and your loved ones from the excesses of an industry gone mad.
Email for Dr. Malhotra consultations
concierge@hum2n.com